Evaxion

Contributing Author

Recent Articles by Evaxion

May-12	Evaxion to present new data for EVX-04, an off-the-shelf therapeutic vaccine for acute myeloid leukemia, at the EHA 2026 Congress EVAX GlobeNewswire
May-07	Evaxion announces business update and first quarter 2026 financial results EVAX -7.71% GlobeNewswire
May-04	Evaxion to announce business update and first quarter 2026 financial results on May 7, 2026 EVAX GlobeNewswire
Apr-27	Evaxion promotes Birgitte Rono to joint role of Chief Scientific and Chief Operating Officer EVAX GlobeNewswire
Apr-17	Evaxion's AI-Immunology platform demonstrates 86% vaccine target precision in phase 2 personalized cancer vaccine trial EVAX +7.49% GlobeNewswire
Apr-17	New data demonstrates the unique scalability of Evaxion's AI-Immunology platform in glioblastoma EVAX +7.49% GlobeNewswire
Apr-16	Evaxion concludes Annual General Meeting EVAX GlobeNewswire
Apr-07	Evaxion announces last patient visit in one-year extension of phase 2 trial with personalized cancer vaccine EVX-01 EVAX GlobeNewswire
Mar-30	Evaxion to present novel AI-based polio vaccine design concepts at the World Vaccine Congress EVAX +7.10% GlobeNewswire
Mar-19	Notice to convene Evaxion's Annual General Meeting EVAX +5.82% GlobeNewswire
Mar-17	Evaxion to present new data at AACR Annual Meeting EVAX GlobeNewswire
Mar-05	Evaxion announces business update and full year 2025 financial results EVAX +9.32% GlobeNewswire
Mar-05	Evaxion plans to file 2025 annual report later today EVAX +9.32% GlobeNewswire
Mar-02	Evaxion to announce business update and full year 2025 financial results on March 5, 2026 EVAX GlobeNewswire
Jan-13	Evaxion expands AI-Immunology platform into autoimmune diseases EVAX GlobeNewswire
Jan-07	Evaxion to present 2026 company milestones at Biotech Showcase conference in San Francisco next week EVAX +6.73% GlobeNewswire
Dec-19	Evaxion provides update on MSD collaboration - retains global rights to Gonorrhea vaccine candidate EVX-B2 EVAX -18.26% GlobeNewswire
Dec-06	Evaxion presents new data for EVX-04, a cancer vaccine candidate for acute myeloid leukemia at ASH Annual Meeting EVAX GlobeNewswire
Nov-20	Evaxion announces positive data for lead antigens in cytomegalovirus (CMV) vaccine program EVX-V1 EVAX +9.43% GlobeNewswire
Nov-12	Evaxion announce 2026 financial calendar EVAX GlobeNewswire
Nov-07	Evaxion presents new immune data from phase 2 trial with AI-designed personalized cancer vaccine EVX-01 EVAX GlobeNewswire
Nov-06	Evaxion announces business update and third quarter 2025 financial results EVAX +10.60% GlobeNewswire
Nov-03	Evaxion expands R&D pipeline with new AI-designed precision cancer vaccine candidate EVAX GlobeNewswire
Oct-31	Correction: Evaxion to announce business update and third quarter 2025 financial results on November 6, 2025 EVAX GlobeNewswire
Oct-31	Evaxion to announce business update and third quarter 2025 financial results on November 6, 2025 EVAX GlobeNewswire
Oct-30	Evaxion raises $7.2 million, extending cash runway to second half of 2027 EVAX GlobeNewswire
Oct-27	Evaxion appoints Dr Helen Tayton-Martin as new Chief Executive Officer EVAX GlobeNewswire
Oct-17	Evaxion reports 75% Objective Response Rate in phase 2 trial with AI-designed personalized cancer vaccine EVX-01 EVAX -29.27% GlobeNewswire
Oct-13	Evaxion to present a breadth of data from phase 2 trial with AI-designed personalized cancer vaccine EVX-01 at the ESMO Congress 2025 EVAX +6.10% GlobeNewswire
Oct-08	Evaxion expands AI-Immunology platform with automated vaccine design module EVAX +9.97% GlobeNewswire
Oct-03	Evaxion to present new biomarker data for AI-designed personalized cancer vaccine EVX-01 at the SITC 2025 Annual Meeting EVAX +14.56% GlobeNewswire
Sep-25	Evaxion out-licenses vaccine candidate EVX-B3 to MSD EVAX +37.27% GlobeNewswire
Aug-27	Evaxion to present at several conferences during the second half of 2025 EVAX GlobeNewswire
Aug-14	Evaxion announces business update and second quarter 2025 financial results EVAX -5.92% GlobeNewswire
Aug-11	Evaxion to announce business update and second quarter 2025 financial results on August 14, 2025 EVAX GlobeNewswire
Jul-25	Evaxion to present two-year clinical efficacy data from phase 2 trial with AI-designed personalized cancer vaccine EVX-01 at the ESMO Congress 2025 EVAX GlobeNewswire
Jul-11	Evaxion finalizes agreement with EIB to convert debt into equity EVAX GlobeNewswire

Evaxion

Recent Articles by Evaxion

Upgrade your Finviz experience